文献速递胸部肿瘤放疗

不同纵隔分期方法对局部晚期非小细胞肺癌靶区勾画的影响:PET-Plan试验次要分析

Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-05

该研究为PET-Plan随机试验的非计划次要分析,纳入172例接受根治性放化疗的局部晚期非小细胞肺癌患者,评估侵入性与非侵入性纵隔分期方法对靶区勾画的影响。结果显示,基于侵入性分期方法,9例患者(10.3%)的13个淋巴结站为PET阴性而侵入性分期阳性,导致靶区显著调整;但侵入性分期未影响结局,孤立性野外复发率低(A组6例 vs B组3例)。作者认为放疗计划可在非侵入性PET基础上结合侵入性分期,需前瞻性随机数据证实。

要点

  • 172例患者中87例(50.6%)接受至少1种侵入性分期方法,每例患者分期操作数量与总生存、无进展生存或局部进展自由时间均无相关性。
  • 基于支气管内超声组织学评估,18F-FDG PET/CT敏感性89.7%(78/87)、特异性67.5%(112/166);基于纵隔镜检查,敏感性82.6%(19/23)、特异性66.7%(36/54)。
  • 基于侵入性分期,9例患者(10.3%)的13个淋巴结站为PET阴性而侵入性分期阳性,导致靶区显著调整。

核心结论

  • 在该非计划次要分析中,额外使用侵入性分期使十分之一患者的靶区发生相关改变。
  • 侵入性分期在本试验中未影响结局,孤立性野外复发率低(A组6例 vs B组3例)。
  • 作者认为,对于接受根治性放化疗的局部晚期非小细胞肺癌患者,放疗计划可在非侵入性PET基础上结合侵入性分期。
  • 作者指出需要前瞻性随机数据来证实这些发现。

研究设计与样本

  • 该研究为前瞻性PET-Plan试验(ARO-2009-09;NCT00697333)的非计划次要分析。
  • 纳入按方案治疗的172例局部晚期非小细胞肺癌患者,均接受等毒性剂量递增放化疗。
  • 放疗计划基于18F-FDG PET/CT:A组靶向所有CT阳性淋巴结(短轴直径>10 mm,即使PET阴性)加选择性淋巴结照射,B组仅靶向PET阳性淋巴结。
  • 计算不同分期方法间的一致率及其对靶区勾画的影响。

主要发现

  • 中位随访时间(95%CI)为41.1(33.8-50.4)个月。
  • 共非侵入性评估2752个淋巴结站,侵入性检查330个。
  • 172例患者中87例(50.6%)接受至少1种侵入性分期方法。
  • 每例患者不同分期操作数量与总生存、无进展生存或局部进展自由时间均无相关性。
  • 基于支气管内超声组织学评估,18F-FDG PET/CT敏感性89.7%(78/87)、特异性67.5%(112/166);基于纵隔镜检查,敏感性82.6%(19/23)、特异性66.7%(36/54)。

关键数值与推荐

  • 18F-FDG PET/CT基于支气管内超声组织学评估的敏感性89.7%(78/87)、特异性67.5%(112/166)。
  • 18F-FDG PET/CT基于纵隔镜检查的敏感性82.6%(19/23)、特异性66.7%(36/54)。
  • 基于侵入性分期,9例患者(10.3%)的13个淋巴结站为PET阴性而侵入性分期阳性,导致靶区显著调整。
  • 孤立性野外复发A组6例 vs B组3例。

临床怎么用

  • 作者认为,对于接受根治性放化疗的局部晚期非小细胞肺癌患者,放疗计划可在非侵入性PET基础上结合侵入性分期。
  • 作者指出需要前瞻性随机数据来证实这些发现。

局限性

  • 该研究为非计划次要分析。
  • 作者指出需要前瞻性随机数据来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the role of different invasive and noninvasive mediastinal staging methods in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation therapy in the prospective PET-Plan trial (ARO-2009-09; NCT00697333) and to evaluate the impact of endobronchial ultrasound-guided transbronchial needle aspiration and mediastinoscopy on target volume definition. METHODS AND MATERIALS: Patients treated per protocol (n = 172), all receiving isotoxically dose-escalated chemoradiation therapy, were included in this unplanned secondary analysis. Radiation treatment planning was based on an 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) targeting all CT-positive lymph nodes (ie, short-axis diameter > 10 mm), even if PET-negative, plus elective nodal irradiation (arm A) or targeting only PET-positive nodes (arm B). The concordance rate between different staging modalities and their impact on target volume delineation was calculated. RESULTS: The median follow-up time (95% confidence interval) was 41.1 (33.8-50.4) months. A total of 2752 lymph node stations were evaluated noninvasively, whereas 330 were examined invasively. Of 172 patients, 87 (50.6%) underwent ≥1 invasive staging modality. The number of different staging procedures per patient did not correlate with any of the primary endpoints (overall survival, progression-free survival, or freedom from local progression). The sensitivity of 18F-FDG PET/CT was 89.7% (78/87) and the specificity was 67.5% (112/166) based on histology as assessed by endobronchial ultrasound. When using the results from mediastinoscopy, the sensitivity of PET was 82.6% (19/23) and the specificity was 66.7% (36/54). On the basis of invasive staging methods, 13 lymph node stations in 9 patients (10.3%) were PET-negative while positive on invasive staging, thus leading to a significant adjustment in the target volume. CONCLUSIONS: In this unplanned secondary analysis of the PET-Plan trial, the additional use of invasive staging resulted in relevant changes to the target volume in a tenth of patients. Invasive staging did not, however, have an effect on outcome in this trial, with a low rate of isolated out-of-field recurrences (6 in arm A vs 3 in arm B). Radiation treatment planning can thus be based on invasive staging in addition to noninvasive PET in patients undergoing definitive chemoradiation therapy for locally advanced non-small cell lung cancer. Prospective randomized data are required to confirm these findings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rimner A, Dejonckheere CS, Sahlmann J, et al. Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40054586. doi:10.1016/j.ijrobp.2025.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。